MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
536.12
+3.30
+0.62%
After Hours: 532.82 -3.3 -0.62% 18:03 03/13 EDT
OPEN
533.83
PREV CLOSE
532.82
HIGH
543.37
LOW
533.83
VOLUME
544.88K
TURNOVER
--
52 WEEK HIGH
548.12
52 WEEK LOW
266.98
MARKET CAP
23.50B
P/E (TTM)
19.24
1D
5D
1M
3M
1Y
5Y
1D
QVAL: Value ETF Lagging Its Peers
Seeking Alpha · 2h ago
Tyvaso IPF Data Puts United Therapeutics Valuation And Growth In Focus
Simply Wall St · 16h ago
What Moved Markets This Week
Seeking Alpha · 1d ago
United Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 2d ago
Cantor Fitzgerald Maintains Overweight on United Therapeutics, Raises Price Target to $625
Benzinga · 2d ago
Oppenheimer Keeps Their Buy Rating on United Therapeutics (UTHR)
TipRanks · 3d ago
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
TipRanks · 3d ago
United Therapeutics price target raised to $625 from $525 at Cantor Fitzgerald
TipRanks · 3d ago
More
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

Webull offers United Therapeutics Corp stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.